JPH09507829A - 増殖分化因子−8 - Google Patents
増殖分化因子−8Info
- Publication number
- JPH09507829A JPH09507829A JP6521293A JP52129394A JPH09507829A JP H09507829 A JPH09507829 A JP H09507829A JP 6521293 A JP6521293 A JP 6521293A JP 52129394 A JP52129394 A JP 52129394A JP H09507829 A JPH09507829 A JP H09507829A
- Authority
- JP
- Japan
- Prior art keywords
- gdf
- antibody
- sequence
- cells
- cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108010056852 Myostatin Proteins 0.000 title claims description 133
- 102000004472 Myostatin Human genes 0.000 title claims 12
- 108091033319 polynucleotide Proteins 0.000 claims abstract description 27
- 102000040430 polynucleotide Human genes 0.000 claims abstract description 27
- 239000002157 polynucleotide Substances 0.000 claims abstract description 27
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 26
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 24
- 229920001184 polypeptide Polymers 0.000 claims abstract description 22
- 210000004027 cell Anatomy 0.000 claims description 81
- 238000000034 method Methods 0.000 claims description 55
- 108090000623 proteins and genes Proteins 0.000 claims description 47
- 108020004414 DNA Proteins 0.000 claims description 43
- 230000014509 gene expression Effects 0.000 claims description 33
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 30
- 239000013598 vector Substances 0.000 claims description 30
- 235000018102 proteins Nutrition 0.000 claims description 26
- 102000004169 proteins and genes Human genes 0.000 claims description 26
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 23
- 239000002502 liposome Substances 0.000 claims description 23
- 201000010099 disease Diseases 0.000 claims description 18
- 230000000692 anti-sense effect Effects 0.000 claims description 15
- 230000002062 proliferating effect Effects 0.000 claims description 15
- 150000007523 nucleic acids Chemical group 0.000 claims description 13
- 230000000694 effects Effects 0.000 claims description 12
- 241000700605 Viruses Species 0.000 claims description 11
- 150000001875 compounds Chemical class 0.000 claims description 11
- 230000008685 targeting Effects 0.000 claims description 11
- 239000012634 fragment Substances 0.000 claims description 10
- 238000001727 in vivo Methods 0.000 claims description 10
- 241001430294 unidentified retrovirus Species 0.000 claims description 10
- 238000001514 detection method Methods 0.000 claims description 9
- 239000013604 expression vector Substances 0.000 claims description 9
- 238000000338 in vitro Methods 0.000 claims description 8
- 210000004962 mammalian cell Anatomy 0.000 claims description 8
- 230000027455 binding Effects 0.000 claims description 7
- 239000013612 plasmid Substances 0.000 claims description 6
- 238000001246 colloidal dispersion Methods 0.000 claims description 5
- 230000000295 complement effect Effects 0.000 claims description 5
- 229930186217 Glycolipid Natural products 0.000 claims description 4
- 239000003795 chemical substances by application Substances 0.000 claims description 4
- 230000001177 retroviral effect Effects 0.000 claims description 4
- 235000000346 sugar Nutrition 0.000 claims description 4
- 230000008878 coupling Effects 0.000 claims description 3
- 238000010168 coupling process Methods 0.000 claims description 3
- 238000005859 coupling reaction Methods 0.000 claims description 3
- 241001493065 dsRNA viruses Species 0.000 claims description 3
- 210000003527 eukaryotic cell Anatomy 0.000 claims description 3
- HVCOBJNICQPDBP-UHFFFAOYSA-N 3-[3-[3,5-dihydroxy-6-methyl-4-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyoxan-2-yl]oxydecanoyloxy]decanoic acid;hydrate Chemical compound O.OC1C(OC(CC(=O)OC(CCCCCCC)CC(O)=O)CCCCCCC)OC(C)C(O)C1OC1C(O)C(O)C(O)C(C)O1 HVCOBJNICQPDBP-UHFFFAOYSA-N 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims description 2
- 150000008163 sugars Chemical class 0.000 claims description 2
- 210000000663 muscle cell Anatomy 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 1
- 210000005260 human cell Anatomy 0.000 claims 1
- 210000001236 prokaryotic cell Anatomy 0.000 claims 1
- 235000004252 protein component Nutrition 0.000 claims 1
- 125000003275 alpha amino acid group Chemical group 0.000 abstract description 25
- 230000004069 differentiation Effects 0.000 abstract description 6
- 230000012010 growth Effects 0.000 abstract description 2
- 102000001690 Factor VIII Human genes 0.000 abstract 1
- 108010054218 Factor VIII Proteins 0.000 abstract 1
- 238000002405 diagnostic procedure Methods 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
- 102100039939 Growth/differentiation factor 8 Human genes 0.000 description 115
- 239000002773 nucleotide Substances 0.000 description 25
- 125000003729 nucleotide group Chemical group 0.000 description 25
- 239000002299 complementary DNA Substances 0.000 description 24
- 235000001014 amino acid Nutrition 0.000 description 23
- 229940024606 amino acid Drugs 0.000 description 23
- 241000699666 Mus <mouse, genus> Species 0.000 description 22
- 150000001413 amino acids Chemical class 0.000 description 20
- 101000886562 Homo sapiens Growth/differentiation factor 8 Proteins 0.000 description 19
- 210000003205 muscle Anatomy 0.000 description 18
- 108020004999 messenger RNA Proteins 0.000 description 17
- 101001075141 Mus musculus Growth/differentiation factor 8 Proteins 0.000 description 15
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 15
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 15
- 239000000523 sample Substances 0.000 description 15
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 15
- 238000003752 polymerase chain reaction Methods 0.000 description 14
- 210000001519 tissue Anatomy 0.000 description 14
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 12
- 210000004899 c-terminal region Anatomy 0.000 description 10
- 208000035475 disorder Diseases 0.000 description 10
- 239000000427 antigen Substances 0.000 description 9
- 102000036639 antigens Human genes 0.000 description 9
- 108091007433 antigens Proteins 0.000 description 9
- 101150004578 gdf-8 gene Proteins 0.000 description 9
- 238000009396 hybridization Methods 0.000 description 9
- 102000053642 Catalytic RNA Human genes 0.000 description 8
- 108090000994 Catalytic RNA Proteins 0.000 description 8
- 108020004705 Codon Proteins 0.000 description 8
- 102000037865 fusion proteins Human genes 0.000 description 8
- 108020001507 fusion proteins Proteins 0.000 description 8
- 108091092562 ribozyme Proteins 0.000 description 8
- 238000011282 treatment Methods 0.000 description 8
- 102000053602 DNA Human genes 0.000 description 7
- 102000043168 TGF-beta family Human genes 0.000 description 7
- 108091085018 TGF-beta family Proteins 0.000 description 7
- 230000004071 biological effect Effects 0.000 description 7
- 230000015572 biosynthetic process Effects 0.000 description 7
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 7
- 238000011161 development Methods 0.000 description 7
- 230000018109 developmental process Effects 0.000 description 7
- 239000000499 gel Substances 0.000 description 7
- 102000039446 nucleic acids Human genes 0.000 description 7
- 108020004707 nucleic acids Proteins 0.000 description 7
- 230000036961 partial effect Effects 0.000 description 7
- 241000894006 Bacteria Species 0.000 description 6
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 6
- 210000000577 adipose tissue Anatomy 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 6
- 210000000349 chromosome Anatomy 0.000 description 6
- 238000003018 immunoassay Methods 0.000 description 6
- 150000002632 lipids Chemical class 0.000 description 6
- 239000002243 precursor Substances 0.000 description 6
- 241000894007 species Species 0.000 description 6
- 238000002955 isolation Methods 0.000 description 5
- 230000003211 malignant effect Effects 0.000 description 5
- 230000004048 modification Effects 0.000 description 5
- 238000012986 modification Methods 0.000 description 5
- 238000012545 processing Methods 0.000 description 5
- 238000006467 substitution reaction Methods 0.000 description 5
- 238000012546 transfer Methods 0.000 description 5
- 108010049955 Bone Morphogenetic Protein 4 Proteins 0.000 description 4
- 102100024505 Bone morphogenetic protein 4 Human genes 0.000 description 4
- 241000588724 Escherichia coli Species 0.000 description 4
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 4
- 108700026244 Open Reading Frames Proteins 0.000 description 4
- 241000283984 Rodentia Species 0.000 description 4
- 210000004900 c-terminal fragment Anatomy 0.000 description 4
- 239000000969 carrier Substances 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 238000003776 cleavage reaction Methods 0.000 description 4
- 238000003745 diagnosis Methods 0.000 description 4
- 238000001415 gene therapy Methods 0.000 description 4
- 230000002068 genetic effect Effects 0.000 description 4
- 239000000893 inhibin Substances 0.000 description 4
- ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 description 4
- 239000003446 ligand Substances 0.000 description 4
- 229930182817 methionine Natural products 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 239000002245 particle Substances 0.000 description 4
- 230000002797 proteolythic effect Effects 0.000 description 4
- 230000006337 proteolytic cleavage Effects 0.000 description 4
- 230000007017 scission Effects 0.000 description 4
- 238000012216 screening Methods 0.000 description 4
- 210000002027 skeletal muscle Anatomy 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- 239000013603 viral vector Substances 0.000 description 4
- 241000287828 Gallus gallus Species 0.000 description 3
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 3
- 241000829100 Macaca mulatta polyomavirus 1 Species 0.000 description 3
- 108091034117 Oligonucleotide Proteins 0.000 description 3
- 241000283973 Oryctolagus cuniculus Species 0.000 description 3
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 3
- 125000000539 amino acid group Chemical group 0.000 description 3
- 235000013330 chicken meat Nutrition 0.000 description 3
- 239000003636 conditioned culture medium Substances 0.000 description 3
- 235000018417 cysteine Nutrition 0.000 description 3
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 230000004927 fusion Effects 0.000 description 3
- 210000003917 human chromosome Anatomy 0.000 description 3
- 210000004754 hybrid cell Anatomy 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- 238000003780 insertion Methods 0.000 description 3
- 230000037431 insertion Effects 0.000 description 3
- -1 isopropylthio Chemical group 0.000 description 3
- 229910052751 metal Inorganic materials 0.000 description 3
- 239000002184 metal Substances 0.000 description 3
- 210000000653 nervous system Anatomy 0.000 description 3
- 238000004806 packaging method and process Methods 0.000 description 3
- 150000003904 phospholipids Chemical class 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 238000003259 recombinant expression Methods 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 238000013519 translation Methods 0.000 description 3
- 230000003612 virological effect Effects 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 2
- 108010059616 Activins Proteins 0.000 description 2
- 108010049870 Bone Morphogenetic Protein 7 Proteins 0.000 description 2
- 108091026890 Coding region Proteins 0.000 description 2
- 241000255581 Drosophila <fruit fly, genus> Species 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
- 241000238631 Hexapoda Species 0.000 description 2
- 108060003951 Immunoglobulin Proteins 0.000 description 2
- 102100026818 Inhibin beta E chain Human genes 0.000 description 2
- 102000000576 Iodoproteins Human genes 0.000 description 2
- 108010041739 Iodoproteins Proteins 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 241000713333 Mouse mammary tumor virus Species 0.000 description 2
- 101710122877 Muellerian-inhibiting factor Proteins 0.000 description 2
- QPCDCPDFJACHGM-UHFFFAOYSA-N N,N-bis{2-[bis(carboxymethyl)amino]ethyl}glycine Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(=O)O)CCN(CC(O)=O)CC(O)=O QPCDCPDFJACHGM-UHFFFAOYSA-N 0.000 description 2
- 230000004988 N-glycosylation Effects 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 239000000020 Nitrocellulose Substances 0.000 description 2
- 108010076504 Protein Sorting Signals Proteins 0.000 description 2
- RADKZDMFGJYCBB-UHFFFAOYSA-N Pyridoxal Chemical compound CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 description 2
- 241000714474 Rous sarcoma virus Species 0.000 description 2
- 241000251131 Sphyrna Species 0.000 description 2
- 241000223892 Tetrahymena Species 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 241000269370 Xenopus <genus> Species 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 239000000488 activin Substances 0.000 description 2
- 210000001789 adipocyte Anatomy 0.000 description 2
- 239000011543 agarose gel Substances 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000000975 bioactive effect Effects 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- 229910000389 calcium phosphate Inorganic materials 0.000 description 2
- 235000011010 calcium phosphates Nutrition 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 230000002759 chromosomal effect Effects 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 210000000805 cytoplasm Anatomy 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 210000002257 embryonic structure Anatomy 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 210000002443 helper t lymphocyte Anatomy 0.000 description 2
- 239000000710 homodimer Substances 0.000 description 2
- 125000001165 hydrophobic group Chemical group 0.000 description 2
- 238000003384 imaging method Methods 0.000 description 2
- 230000003053 immunization Effects 0.000 description 2
- 238000002649 immunization Methods 0.000 description 2
- 102000018358 immunoglobulin Human genes 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 238000002595 magnetic resonance imaging Methods 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 229910021645 metal ion Inorganic materials 0.000 description 2
- 239000000693 micelle Substances 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 230000037230 mobility Effects 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 210000003098 myoblast Anatomy 0.000 description 2
- 230000004770 neurodegeneration Effects 0.000 description 2
- 208000015122 neurodegenerative disease Diseases 0.000 description 2
- 229920001220 nitrocellulos Polymers 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 230000005298 paramagnetic effect Effects 0.000 description 2
- 229960003330 pentetic acid Drugs 0.000 description 2
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 2
- 210000002826 placenta Anatomy 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 238000003127 radioimmunoassay Methods 0.000 description 2
- 238000005215 recombination Methods 0.000 description 2
- 230000010076 replication Effects 0.000 description 2
- 230000000717 retained effect Effects 0.000 description 2
- 238000010839 reverse transcription Methods 0.000 description 2
- FGDZQCVHDSGLHJ-UHFFFAOYSA-M rubidium chloride Chemical compound [Cl-].[Rb+] FGDZQCVHDSGLHJ-UHFFFAOYSA-M 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 238000002741 site-directed mutagenesis Methods 0.000 description 2
- 210000001082 somatic cell Anatomy 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000001890 transfection Methods 0.000 description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- BRZYSWJRSDMWLG-DJWUNRQOSA-N (2r,3r,4r,5r)-2-[(1s,2s,3r,4s,6r)-4,6-diamino-3-[(2s,3r,4r,5s,6r)-3-amino-4,5-dihydroxy-6-[(1r)-1-hydroxyethyl]oxan-2-yl]oxy-2-hydroxycyclohexyl]oxy-5-methyl-4-(methylamino)oxane-3,5-diol Chemical compound O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H]([C@@H](C)O)O2)N)[C@@H](N)C[C@H]1N BRZYSWJRSDMWLG-DJWUNRQOSA-N 0.000 description 1
- NRJAVPSFFCBXDT-HUESYALOSA-N 1,2-distearoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC NRJAVPSFFCBXDT-HUESYALOSA-N 0.000 description 1
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 description 1
- UFBJCMHMOXMLKC-UHFFFAOYSA-N 2,4-dinitrophenol Chemical compound OC1=CC=C([N+]([O-])=O)C=C1[N+]([O-])=O UFBJCMHMOXMLKC-UHFFFAOYSA-N 0.000 description 1
- ZSLUVFAKFWKJRC-IGMARMGPSA-N 232Th Chemical compound [232Th] ZSLUVFAKFWKJRC-IGMARMGPSA-N 0.000 description 1
- OALHHIHQOFIMEF-UHFFFAOYSA-N 3',6'-dihydroxy-2',4',5',7'-tetraiodo-3h-spiro[2-benzofuran-1,9'-xanthene]-3-one Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC(I)=C(O)C(I)=C1OC1=C(I)C(O)=C(I)C=C21 OALHHIHQOFIMEF-UHFFFAOYSA-N 0.000 description 1
- QFVHZQCOUORWEI-UHFFFAOYSA-N 4-[(4-anilino-5-sulfonaphthalen-1-yl)diazenyl]-5-hydroxynaphthalene-2,7-disulfonic acid Chemical compound C=12C(O)=CC(S(O)(=O)=O)=CC2=CC(S(O)(=O)=O)=CC=1N=NC(C1=CC=CC(=C11)S(O)(=O)=O)=CC=C1NC1=CC=CC=C1 QFVHZQCOUORWEI-UHFFFAOYSA-N 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 241000972773 Aulopiformes Species 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 241000714235 Avian retrovirus Species 0.000 description 1
- 108090001008 Avidin Proteins 0.000 description 1
- 108010049931 Bone Morphogenetic Protein 2 Proteins 0.000 description 1
- 108010049951 Bone Morphogenetic Protein 3 Proteins 0.000 description 1
- 102100024506 Bone morphogenetic protein 2 Human genes 0.000 description 1
- 102100024504 Bone morphogenetic protein 3 Human genes 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 241000701822 Bovine papillomavirus Species 0.000 description 1
- 102100021391 Cationic amino acid transporter 3 Human genes 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 241000699802 Cricetulus griseus Species 0.000 description 1
- 206010011732 Cyst Diseases 0.000 description 1
- 238000007399 DNA isolation Methods 0.000 description 1
- 230000007023 DNA restriction-modification system Effects 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
- 102100040897 Embryonic growth/differentiation factor 1 Human genes 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 229920001917 Ficoll Polymers 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 description 1
- 108010090296 Growth Differentiation Factor 1 Proteins 0.000 description 1
- 108010090293 Growth Differentiation Factor 3 Proteins 0.000 description 1
- 108010090254 Growth Differentiation Factor 5 Proteins 0.000 description 1
- 102100035364 Growth/differentiation factor 3 Human genes 0.000 description 1
- 102100035379 Growth/differentiation factor 5 Human genes 0.000 description 1
- 208000009889 Herpes Simplex Diseases 0.000 description 1
- 101000762366 Homo sapiens Bone morphogenetic protein 2 Proteins 0.000 description 1
- 101000762375 Homo sapiens Bone morphogenetic protein 3 Proteins 0.000 description 1
- 101000762379 Homo sapiens Bone morphogenetic protein 4 Proteins 0.000 description 1
- 101000899388 Homo sapiens Bone morphogenetic protein 5 Proteins 0.000 description 1
- 101000899361 Homo sapiens Bone morphogenetic protein 7 Proteins 0.000 description 1
- 101000893552 Homo sapiens Embryonic growth/differentiation factor 1 Proteins 0.000 description 1
- 101001011645 Homo sapiens Muellerian-inhibiting factor Proteins 0.000 description 1
- 101000800133 Homo sapiens Thyroglobulin Proteins 0.000 description 1
- 101500025614 Homo sapiens Transforming growth factor beta-1 Proteins 0.000 description 1
- 101500025624 Homo sapiens Transforming growth factor beta-2 Proteins 0.000 description 1
- 208000011823 Juvenile amyotrophic lateral sclerosis Diseases 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- 101000844802 Lacticaseibacillus rhamnosus Teichoic acid D-alanyltransferase Proteins 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 239000000232 Lipid Bilayer Substances 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 241001024304 Mino Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 238000000636 Northern blotting Methods 0.000 description 1
- 102000011931 Nucleoproteins Human genes 0.000 description 1
- 108010061100 Nucleoproteins Proteins 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 108020005187 Oligonucleotide Probes Proteins 0.000 description 1
- 108010038807 Oligopeptides Proteins 0.000 description 1
- 102000015636 Oligopeptides Human genes 0.000 description 1
- 208000012868 Overgrowth Diseases 0.000 description 1
- 241000282376 Panthera tigris Species 0.000 description 1
- 101000851110 Periplaneta americana Vitellogenin-1 Proteins 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 101710182846 Polyhedrin Proteins 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 108020004518 RNA Probes Proteins 0.000 description 1
- 238000002123 RNA extraction Methods 0.000 description 1
- 239000003391 RNA probe Substances 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 108091006230 SLC7A3 Proteins 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- 108020004682 Single-Stranded DNA Proteins 0.000 description 1
- 244000061458 Solanum melongena Species 0.000 description 1
- 235000002597 Solanum melongena Nutrition 0.000 description 1
- 238000002105 Southern blotting Methods 0.000 description 1
- 208000037065 Subacute sclerosing leukoencephalitis Diseases 0.000 description 1
- 206010042297 Subacute sclerosing panencephalitis Diseases 0.000 description 1
- 229910052776 Thorium Inorganic materials 0.000 description 1
- 108010022394 Threonine synthase Proteins 0.000 description 1
- 108020004440 Thymidine kinase Proteins 0.000 description 1
- 108020004566 Transfer RNA Proteins 0.000 description 1
- 102000011117 Transforming Growth Factor beta2 Human genes 0.000 description 1
- 102000009618 Transforming Growth Factors Human genes 0.000 description 1
- 108010009583 Transforming Growth Factors Proteins 0.000 description 1
- 101800000304 Transforming growth factor beta-2 Proteins 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 241000700618 Vaccinia virus Species 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- 108010003533 Viral Envelope Proteins Proteins 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 238000007259 addition reaction Methods 0.000 description 1
- 230000002293 adipogenic effect Effects 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 238000003277 amino acid sequence analysis Methods 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 230000019552 anatomical structure morphogenesis Effects 0.000 description 1
- 230000006427 angiogenic response Effects 0.000 description 1
- 239000012062 aqueous buffer Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 150000001483 arginine derivatives Chemical class 0.000 description 1
- 238000003491 array Methods 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N aspartic acid group Chemical class N[C@@H](CC(=O)O)C(=O)O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 239000013060 biological fluid Substances 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 230000022159 cartilage development Effects 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 229930183167 cerebroside Natural products 0.000 description 1
- 150000001784 cerebrosides Chemical class 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000003610 charcoal Substances 0.000 description 1
- 239000013522 chelant Substances 0.000 description 1
- 230000009920 chelation Effects 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 238000003200 chromosome mapping Methods 0.000 description 1
- 238000000975 co-precipitation Methods 0.000 description 1
- 230000037319 collagen production Effects 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 238000002967 competitive immunoassay Methods 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 208000031513 cyst Diseases 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 229960002086 dextran Drugs 0.000 description 1
- 229960000633 dextran sulfate Drugs 0.000 description 1
- 239000000032 diagnostic agent Substances 0.000 description 1
- 229940039227 diagnostic agent Drugs 0.000 description 1
- 238000002059 diagnostic imaging Methods 0.000 description 1
- 102000004419 dihydrofolate reductase Human genes 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 238000006471 dimerization reaction Methods 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000009786 epithelial differentiation Effects 0.000 description 1
- DNJIEGIFACGWOD-UHFFFAOYSA-N ethyl mercaptane Natural products CCS DNJIEGIFACGWOD-UHFFFAOYSA-N 0.000 description 1
- 239000013613 expression plasmid Substances 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 238000007499 fusion processing Methods 0.000 description 1
- 150000002270 gangliosides Chemical class 0.000 description 1
- 238000003205 genotyping method Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 150000002308 glutamine derivatives Chemical class 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 230000011132 hemopoiesis Effects 0.000 description 1
- 239000008241 heterogeneous mixture Substances 0.000 description 1
- 102000045896 human BMP2 Human genes 0.000 description 1
- 102000046148 human BMP4 Human genes 0.000 description 1
- 102000046107 human BMP7 Human genes 0.000 description 1
- 102000054677 human MSTN Human genes 0.000 description 1
- 102000047688 human TG Human genes 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 230000014726 immortalization of host cell Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 230000002055 immunohistochemical effect Effects 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 238000011503 in vivo imaging Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 125000005647 linker group Chemical group 0.000 description 1
- 125000003473 lipid group Chemical group 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L magnesium chloride Substances [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 230000005291 magnetic effect Effects 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 230000013011 mating Effects 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000007721 medicinal effect Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 210000004779 membrane envelope Anatomy 0.000 description 1
- 210000003716 mesoderm Anatomy 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 238000000520 microinjection Methods 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 210000000865 mononuclear phagocyte system Anatomy 0.000 description 1
- 210000002161 motor neuron Anatomy 0.000 description 1
- 230000001114 myogenic effect Effects 0.000 description 1
- 230000032405 negative regulation of neuron apoptotic process Effects 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 210000000944 nerve tissue Anatomy 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 230000006576 neuronal survival Effects 0.000 description 1
- 230000036963 noncompetitive effect Effects 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 238000007899 nucleic acid hybridization Methods 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- 125000003835 nucleoside group Chemical group 0.000 description 1
- 210000004940 nucleus Anatomy 0.000 description 1
- 235000003170 nutritional factors Nutrition 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 239000002751 oligonucleotide probe Substances 0.000 description 1
- 210000004789 organ system Anatomy 0.000 description 1
- 210000003463 organelle Anatomy 0.000 description 1
- 230000011164 ossification Effects 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 238000007747 plating Methods 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 238000004237 preparative chromatography Methods 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 238000001742 protein purification Methods 0.000 description 1
- 210000001938 protoplast Anatomy 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 229960003581 pyridoxal Drugs 0.000 description 1
- 235000008164 pyridoxal Nutrition 0.000 description 1
- 239000011674 pyridoxal Substances 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 102220201851 rs143406017 Human genes 0.000 description 1
- 235000019515 salmon Nutrition 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 238000006884 silylation reaction Methods 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- FQENQNTWSFEDLI-UHFFFAOYSA-J sodium diphosphate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]P([O-])(=O)OP([O-])([O-])=O FQENQNTWSFEDLI-UHFFFAOYSA-J 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 229940048086 sodium pyrophosphate Drugs 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 238000010129 solution processing Methods 0.000 description 1
- 230000000392 somatic effect Effects 0.000 description 1
- 150000003408 sphingolipids Chemical class 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 235000019818 tetrasodium diphosphate Nutrition 0.000 description 1
- 239000001577 tetrasodium phosphonato phosphate Substances 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 125000000430 tryptophan group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C2=C([H])C([H])=C([H])C([H])=C12 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 241000701447 unidentified baculovirus Species 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 239000002691 unilamellar liposome Substances 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
- 239000011800 void material Substances 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
- 239000012130 whole-cell lysate Substances 0.000 description 1
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/495—Transforming growth factor [TGF]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1.実質的に純粋な増殖分化因子−8(GDF−8)及びその機能性断片。 2.請求項1のGDF−8ポリペプチドをコードする単離されたポリヌクレオチ ド配列。 3.GDF−8ポリヌクレオチド配列が下記の核酸配列からなる群から選ばれる 、請求項2のポリヌクレオチド。 a.TがUであってもよい図5a; b.TがUであってもよい図5b; c.図5aに相補的な核酸配列; d.図5bに相補的な核酸配列; e.長さが少なくとも15塩基であり、図5aのGDF−8タンパク質をコー ドするゲノミックDNAに選択的にハイブリダイズするaまたはcの断片;及び f.長さが少なくとも15塩基であり、図5bのGDF−8タンパク質をコー ドするゲノミックDNAに選択的にハイブリダイズするb又はdの断片。 4.ポリヌクレオチドが哺乳動物細胞から単離される、請求項2のポリヌクレオ チド配列。 5.哺乳動物細胞がマウス、ラット、及びヒトの細胞からなる群から選ばれる、 請求項4のポリヌクレオチド。 6.請求項2のポリヌクレオチドを含む発現ベクター。 7.プラスミドである、請求項6のベクター。 8.ウィルスである、請求項6のベクター。 9.請求項6のベクターで安定に形質転換された宿主細胞。 10.細胞が原核細胞である、請求項9の宿主細胞。 11.細胞が真核細胞である、請求項9の宿主細胞。 12.請求項1のポリペプチド又はその断片と反応性の抗体。 13.ポリクローナルである、請求項12の抗体。 14.モノクローナルである、請求項12の抗体。 15.細胞増殖性疾患を検出する方法であって、請求項12の抗体をGDF−8関連 疾患を有する疑いがある被験体の検体と接触させ、そして該抗体の結合を検出す ることを含む方法。 16.細胞が筋細胞である、請求項15の方法。 17.検出がin vivoである、請求項15の方法。 18.抗体が検出できるように標識されている、請求項17の方法。 19.検出できる標識が、放射性同位元素、蛍光化合物、生物発光化合物、及び化 学発光化合物からなる群から選ばれる、請求項18の方法。 20.検出がin vitroである、請求項15の方法。 21.抗体が検出できるように標識されている、請求項20の方法。 22.標識が、放射性同位元素、蛍光化合物、生物発光化合物、化学発光化合物、 及び酵素からなる群から選ばれる、請求項21の方法。 23.GDF−8の発現と関連する細胞増殖性疾患を治療する方法であって、該細 胞をGDF−8活性を抑制する薬剤と接触させることを含む方法。 24.薬剤が抗GDF−8抗体である、請求項23の方法。 25.薬剤がGDF−8アンチセンス配列である、請求項23の方法。 26.細胞が筋細胞である、請求項23の方法。 27.GDF−8活性を抑制する薬剤がベクターを用いて細胞に導入される、請求 項23の方法。 28.ベクターがコロイド状分散系である、請求項27の方法。 29.コロイド状分散系がリポソームである、請求項28の方法。 30.リポソームが本質的に標的特異性である、請求項29の方法。 31.リポソームが解剖学的にターゲッティングされている、請求項30の方法。 32.リポソームが機械学的にターゲッティングされている、請求項31の方法。 33.機械学的ターゲッティングが受動的なものである、請求項32の方法。 34.機械学的ターゲッティングが能動的なものである、請求項32の方法。 35.リポソームが、糖、糖脂質、及びタンパク質からなる群から選ばれる成分と カップリングすることにより能動的にターゲッティングされている、請求項34の 方法。 36.タンパク質成分が抗体である、請求項35の方法。 37.ベクターがウィルスである、請求項36の方法。 38.ウィルスがRNAウィルスである、請求項37の方法。 39.RNAウィルスがレトロウィルスである、請求項38の方法。 40.レトロウィルスが本質的に標的特異性である、請求項39の方法。 41.標的特異性の成分がレトロウィルスゲノムの中に挿入されたポリヌクレオチ ドによりコードされる、請求項40の方法。 42.標的特異性の成分が、糖、糖脂質、及びタンパク質からなる群から選ばれる 、請求項40の方法。 43.タンパク質が抗体である、請求項42の方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US3392393A | 1993-03-19 | 1993-03-19 | |
US08/033,923 | 1993-03-19 | ||
PCT/US1994/003019 WO1994021681A1 (en) | 1993-03-19 | 1994-03-18 | Growth differentiation factor-8 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2004001012A Division JP2004121265A (ja) | 1993-03-19 | 2004-01-06 | 増殖分化因子−8 |
Publications (1)
Publication Number | Publication Date |
---|---|
JPH09507829A true JPH09507829A (ja) | 1997-08-12 |
Family
ID=21873232
Family Applications (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP6521293A Pending JPH09507829A (ja) | 1993-03-19 | 1994-03-18 | 増殖分化因子−8 |
JP2004001012A Pending JP2004121265A (ja) | 1993-03-19 | 2004-01-06 | 増殖分化因子−8 |
JP2005326630A Pending JP2006117682A (ja) | 1993-03-19 | 2005-11-10 | 増殖分化因子−8 |
JP2007125060A Pending JP2007306920A (ja) | 1993-03-19 | 2007-05-09 | 増殖分化因子−8 |
Family Applications After (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2004001012A Pending JP2004121265A (ja) | 1993-03-19 | 2004-01-06 | 増殖分化因子−8 |
JP2005326630A Pending JP2006117682A (ja) | 1993-03-19 | 2005-11-10 | 増殖分化因子−8 |
JP2007125060A Pending JP2007306920A (ja) | 1993-03-19 | 2007-05-09 | 増殖分化因子−8 |
Country Status (8)
Country | Link |
---|---|
US (5) | US5827733A (ja) |
EP (2) | EP1333035A3 (ja) |
JP (4) | JPH09507829A (ja) |
CA (1) | CA2157577C (ja) |
DE (1) | DE69432815T2 (ja) |
DK (1) | DK0690873T3 (ja) |
ES (1) | ES2201076T3 (ja) |
WO (1) | WO1994021681A1 (ja) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2004504826A (ja) * | 2000-07-27 | 2004-02-19 | ザ ジョーンズ ホプキンス ユニバーシティー スクール オブ メディシン | プロミオスタチンペプチドおよびその使用法 |
JP2007535912A (ja) * | 2003-12-31 | 2007-12-13 | シェーリング−プラウ・リミテッド | 中和エピトープベースの増殖増強性ワクチン |
Families Citing this family (147)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE69233022T2 (de) | 1991-11-04 | 2004-02-12 | Genetics Institute, LLC, Cambridge | Rekombinante knochenmorphogenetische protein heterodimere, zusammensetzungen und verfahren zur verwendung |
EP1333035A3 (en) | 1993-03-19 | 2004-07-07 | The Johns Hopkins University School Of Medicine | Growth differentiation factor-8 |
US6465239B1 (en) * | 1993-03-19 | 2002-10-15 | The John Hopkins University School Of Medicine | Growth differentiation factor-8 nucleic acid and polypeptides from aquatic species and non-human transgenic aquatic species |
US7566768B1 (en) | 1995-10-26 | 2009-07-28 | The Johns Hopkins University School Of Medicine | Promyostatin peptides and methods of using same |
US6607884B1 (en) | 1993-03-19 | 2003-08-19 | The Johns Hopkins University School Of Medicine | Methods of detecting growth differentiation factor-8 |
US20030074680A1 (en) * | 1993-03-19 | 2003-04-17 | Johns Hopkins University School Of Medicine | Growth differentiation factor-8 |
US5994618A (en) | 1997-02-05 | 1999-11-30 | Johns Hopkins University School Of Medicine | Growth differentiation factor-8 transgenic mice |
DE69433530T2 (de) | 1993-05-12 | 2005-01-05 | Genetics Institute, LLC, Cambridge | Bmp-11 zusammensetzungen |
US6713302B1 (en) * | 1993-07-09 | 2004-03-30 | The Johns Hopkins University School Of Medicine | Growth differentiation factor-6 |
US7332575B2 (en) | 1994-03-18 | 2008-02-19 | The Johns Hopkins University School Of Medicine | Growth differentiation factor-8 nucleic acid and polypeptide from aquatic species, and transgenic aquatic species |
US20030167492A1 (en) | 1994-07-08 | 2003-09-04 | Johns Hopkins University School Of Medicine | Transgenic non-human animals expressing a gdf-11 dominant negative polypeptide, and methods of making and using same |
US6008434A (en) | 1994-07-08 | 1999-12-28 | Johns Hopkins University School Of Medicine | Growth differentiation factor-11 transgenic mice |
ATE305036T1 (de) * | 1994-07-08 | 2005-10-15 | Univ Johns Hopkins Med | Wachstums-differenzierungsfaktor-11 |
US5846770A (en) * | 1994-11-22 | 1998-12-08 | Genetics Institute, Inc. | DNA molecules encoding human chordin |
US5635372A (en) * | 1995-05-18 | 1997-06-03 | Genetics Institute, Inc. | BMP-15 compositions |
DK1364656T3 (da) | 1995-06-05 | 2013-12-16 | Genetics Inst Llc | Brug af knoglemorfogenetiske proteiner til heling og reparation af bindevævsvedhæftning |
US5700774A (en) * | 1996-03-26 | 1997-12-23 | Genetics Institute, Inc. | Compositions comprising bone morphogenic proteins and truncated parathyroid hormone related peptide, and methods of inducing cartilage by administration of same |
US5965403A (en) | 1996-09-18 | 1999-10-12 | Genetics Institute, Inc. | Nucleic acids encoding bone morphogenic protein-16 (BMP-16) |
US20010016646A1 (en) | 1998-03-20 | 2001-08-23 | David C. Rueger | Osteogenic devices and methods of use thereof for repair of endochondral bone, osteochondral and chondral defects |
US7041641B2 (en) | 1997-03-20 | 2006-05-09 | Stryker Corporation | Osteogenic devices and methods of use thereof for repair of endochondral bone and osteochondral defects |
EP2309261A1 (en) | 1997-05-30 | 2011-04-13 | Stryker Corporation | Methods for evaluating tissue morphogenesis and morphogenic activity |
DK2045322T3 (en) * | 1997-07-14 | 2015-10-05 | Université de Liège | DOUBLE MUSCULAR FOR MAMMALS |
US6103466A (en) * | 1997-07-14 | 2000-08-15 | University Of Liege | Double-muscling in mammals |
US20070067859A1 (en) * | 1997-07-14 | 2007-03-22 | Michel Georges | Double-muscling in mammals |
US6656475B1 (en) * | 1997-08-01 | 2003-12-02 | The Johns Hopkins University School Of Medicine | Growth differentiation factor receptors, agonists and antagonists thereof, and methods of using same |
US6891082B2 (en) * | 1997-08-01 | 2005-05-10 | The Johns Hopkins University School Of Medicine | Transgenic non-human animals expressing a truncated activintype II receptor |
US6696260B1 (en) * | 1997-08-01 | 2004-02-24 | The Johns Hopkins University School Of Medicine | Methods to identify growth differentiation factor (GDF) binding proteins |
US20020052026A1 (en) | 1997-10-08 | 2002-05-02 | Steven M. Vicik | Methods of refolding proteins |
US6027917A (en) | 1997-12-10 | 2000-02-22 | Genetics Institute, Inc. | Bone morphogenetic protein (BMP)-17 and BMP-18 compositions |
WO1999040181A1 (en) * | 1998-02-05 | 1999-08-12 | The Johns Hopkins University School Of Medicine | Growth differentiation factor-8 |
US6369201B1 (en) * | 1998-02-19 | 2002-04-09 | Metamorphix International, Inc. | Myostatin multimers |
US6004937A (en) * | 1998-03-09 | 1999-12-21 | Genetics Institute, Inc. | Use of follistatin to modulate growth and differentiation factor 8 [GDF-8] and bone morphogenic protein 11 [BMP-11] |
CA2331410C (en) | 1998-05-06 | 2009-07-14 | Metamorphix, Inc. | Methods for treating diabetes by inhibiting gdf-8 |
US7147839B2 (en) | 1998-05-29 | 2006-12-12 | Curis, Inc. | Methods for evaluating tissue morphogenesis and activity |
US6555672B1 (en) * | 1998-07-15 | 2003-04-29 | Metamorphix, Inc. | Growth differentiation factor promoter and uses therefor |
BR0008188A (pt) * | 1999-01-21 | 2002-02-13 | Metamorphix Inc | Inibidores de fator de diferenciação de crescimento e usos para os mesmos |
US6727224B1 (en) | 1999-02-01 | 2004-04-27 | Genetics Institute, Llc. | Methods and compositions for healing and repair of articular cartilage |
DE19906096A1 (de) | 1999-02-13 | 2000-08-17 | Walter Sebald | Protein mit einem Heparin-bindenden Epitop |
US6284882B1 (en) * | 1999-06-10 | 2001-09-04 | Abbott Laboratories | Myostatin gene promoter and inhibition of activation thereof |
AU4889100A (en) | 1999-07-30 | 2001-02-01 | Pfizer Products Inc. | Myostatin regulatory region, nucleotide sequence determination and methods for its use |
US6756215B1 (en) * | 2000-10-20 | 2004-06-29 | The United States Of America As Represented By The Secretary Of The Department Of Health & Human Services | Functionalized TGF-β fusion proteins |
US7037501B2 (en) * | 2001-01-04 | 2006-05-02 | Regents Of The University Of Minnesota | Myostatin immnoconjugate |
TWI329129B (en) | 2001-02-08 | 2010-08-21 | Wyeth Corp | Modified and stabilized gdf propeptides and uses thereof |
KR100420798B1 (ko) * | 2001-02-10 | 2004-03-02 | (주)알에이싸이언스 | 펩타이드 벡터 |
TWI267378B (en) | 2001-06-08 | 2006-12-01 | Wyeth Corp | Calcium phosphate delivery vehicles for osteoinductive proteins |
US7320789B2 (en) * | 2001-09-26 | 2008-01-22 | Wyeth | Antibody inhibitors of GDF-8 and uses thereof |
US6798160B2 (en) * | 2001-11-02 | 2004-09-28 | Honda Giken Kogyo Kabushiki Kaisha | Electric working machine |
MXPA04008150A (es) | 2002-02-21 | 2005-06-17 | Wyeth Corp | Gasp1: una proteina que contiene dominio de folistatina. |
US7572763B2 (en) | 2002-02-21 | 2009-08-11 | Wyeth | Follistatin domain containing proteins |
US20040138118A1 (en) * | 2002-09-16 | 2004-07-15 | Neil Wolfman | Metalloprotease activation of myostatin, and methods of modulating myostatin activity |
US7261893B2 (en) | 2002-10-22 | 2007-08-28 | Wyeth | Neutralizing antibodies against GDF-8 and uses therefor |
US20040223966A1 (en) * | 2002-10-25 | 2004-11-11 | Wolfman Neil M. | ActRIIB fusion polypeptides and uses therefor |
KR20150107899A (ko) | 2002-12-20 | 2015-09-23 | 암겐 인코포레이티드 | 미오스타틴을 저해하는 결합제 |
BRPI0410927A (pt) * | 2003-06-02 | 2006-06-27 | Wyeth Corp | métodos terapêuticos e profiláticos para distúrbios neuromusculares |
BRPI0413720A (pt) | 2003-09-12 | 2006-10-17 | Wyeth Corp | bastões e pastas sólidas de fosfato de cálcio injetável para liberação de proteìnas osteogênicas |
CN1938194B (zh) | 2004-03-10 | 2013-06-05 | 希尔技术股份有限公司 | 涂层植入物、及其制造和应用 |
ATE557042T1 (de) * | 2004-03-23 | 2012-05-15 | Lilly Co Eli | Anti-myostatin-antikörper |
JP4688483B2 (ja) * | 2004-04-15 | 2011-05-25 | 株式会社テクノネットワーク四国 | フォリスタチン変異体ポリペプチド |
CA2563374A1 (en) | 2004-04-27 | 2005-12-08 | Research Development Foundation | Antagonism of tgf-.beta.superfamily receptor signaling |
ES2369629T3 (es) | 2004-05-25 | 2011-12-02 | Stryker Corporation | Uso de op-1 para tratar defectos del cartílago. |
CN101001642A (zh) * | 2004-08-12 | 2007-07-18 | 惠氏公司 | 使用gdf-8抑制剂对糖尿病、肥胖症和心血管病的联合治疗 |
US7473678B2 (en) | 2004-10-14 | 2009-01-06 | Biomimetic Therapeutics, Inc. | Platelet-derived growth factor compositions and methods of use thereof |
US7799754B2 (en) | 2004-10-14 | 2010-09-21 | Biomimetic Therapeutics, Inc. | Compositions and methods for treating bone |
MY144766A (en) | 2004-12-30 | 2011-10-31 | Schering Plough Ltd | Plant virus coat fusion proteins with gdf8 epitopes and vaccines thereof |
US20060166251A1 (en) * | 2005-01-26 | 2006-07-27 | Archambault Joanne M | Use of sFRPs as markers of BMP activity |
AU2006213686A1 (en) | 2005-02-09 | 2006-08-17 | Avi Bio Pharma, Inc. | Antisense composition and method for treating muscle atrophy |
MX2007011405A (es) * | 2005-03-23 | 2007-10-11 | Wyeth Corp | Deteccion de una respuesta inmune para agentes moduladores de crecimiento y la diferenciacion del factor 8 (gdf 8). |
MX2007011591A (es) * | 2005-03-30 | 2007-12-10 | Wyeth Corp | Metodo para estimular el crecimiento de cabello administrando bmps. |
US7888486B2 (en) | 2005-08-19 | 2011-02-15 | Wyeth Llc | Antagonist antibodies against GDF-8 |
CA2624976A1 (en) | 2005-10-06 | 2007-04-19 | Eli Lilly And Company | Anti-myostatin antibodies |
UA92504C2 (en) | 2005-10-12 | 2010-11-10 | Эли Лилли Энд Компани | Anti-myostatin monoclonal antibody |
US8067562B2 (en) | 2005-11-01 | 2011-11-29 | Amgen Inc. | Isolated nucleic acid molecule comprising the amino acid sequence of SEQ ID NO:1 |
MX2008007324A (es) * | 2005-12-06 | 2009-03-04 | Amgen Inc | Usos de antagonistas de miostatina. |
US8147860B2 (en) | 2005-12-06 | 2012-04-03 | Etex Corporation | Porous calcium phosphate bone material |
CN104761637B (zh) | 2006-03-31 | 2021-10-15 | 中外制药株式会社 | 调控抗体血液动力学的方法 |
CA2652549A1 (en) | 2006-05-17 | 2007-12-13 | Stryker Corporation | Use of a soluble morphogenic protein complex for treating cartilage defects |
ES2664229T3 (es) | 2006-06-30 | 2018-04-18 | Biomimetic Therapeutics, Llc | Composiciones y métodos de biomatriz-PDGF para el tratamiento de lesiones del manguito rotador |
US9161967B2 (en) | 2006-06-30 | 2015-10-20 | Biomimetic Therapeutics, Llc | Compositions and methods for treating the vertebral column |
US8524265B2 (en) | 2006-08-17 | 2013-09-03 | Warsaw Orthopedic, Inc. | Medical implant sheets useful for tissue regeneration |
JP5058261B2 (ja) | 2006-09-05 | 2012-10-24 | イーライ リリー アンド カンパニー | 抗ミオスタチン抗体 |
AU2007234612B2 (en) | 2006-12-14 | 2013-06-27 | Johnson & Johnson Regenerative Therapeutics, Llc | Protein stabilization formulations |
JP5452230B2 (ja) | 2006-12-21 | 2014-03-26 | ストライカー コーポレイション | 生物学的因子の結晶、高分子ゲルおよび粒子懸濁液を含む持続放出処方物 |
US7947646B2 (en) | 2007-03-06 | 2011-05-24 | Amgen Inc. | Variant activin receptor polypeptides |
US8501678B2 (en) | 2007-03-06 | 2013-08-06 | Atara Biotherapeutics, Inc. | Variant activin receptor polypeptides and uses thereof |
US8236751B2 (en) * | 2007-03-07 | 2012-08-07 | The Johns Hopkins University | Methods of increasing muscle mass using follistatin-like related gene (FLRG) |
US7678764B2 (en) | 2007-06-29 | 2010-03-16 | Johnson & Johnson Regenerative Therapeutics, Llc | Protein formulations for use at elevated temperatures |
GB0715087D0 (en) | 2007-08-03 | 2007-09-12 | Summit Corp Plc | Drug combinations for the treatment of duchenne muscular dystrophy |
MX2009012558A (es) | 2007-08-03 | 2010-04-21 | Biomarin Iga Ltd | Combinaciones de farmacos para el tratamiento de distrofia muscular de duchenne. |
WO2009020744A1 (en) | 2007-08-07 | 2009-02-12 | Johnson & Johnson Regenerative Therapeutics, Llc | Protein formulations comprising gdf-5 in aqueous acidic solution |
EP3127921A1 (en) | 2007-09-26 | 2017-02-08 | Chugai Seiyaku Kabushiki Kaisha | Method of modifying isoelectric point of antibody via amino acid substition in cdr |
JP2011514331A (ja) | 2008-02-13 | 2011-05-06 | キース フルスカ, | 血管硬化症の治療における使用のためのbmp−7 |
WO2009111793A2 (en) | 2008-03-07 | 2009-09-11 | Myoscience, Inc. | Subdermal tissue remodeling using myostatin, methods and related systems |
TWI564021B (zh) | 2008-04-11 | 2017-01-01 | Chugai Pharmaceutical Co Ltd | Repeated binding of antigen to antigen binding molecules |
CN102026619A (zh) | 2008-04-14 | 2011-04-20 | 先进科技及再生医学有限责任公司 | 液体缓冲的gdf-5制剂 |
BR122020000059B8 (pt) | 2008-09-09 | 2021-06-22 | Biomimetic Therapeutics Inc | composição que compreende uma matriz biocompatível e um fator de crescimento derivado de plaqueta e kit |
UA107921C2 (en) | 2008-11-26 | 2015-03-10 | Amgen Inc | Variants of polypeptide of receptor ivr activin and their use |
AR074777A1 (es) | 2008-12-19 | 2011-02-09 | Glaxo Group Ltd | Proteinas de union a antigeno |
WO2010093941A2 (en) | 2009-02-12 | 2010-08-19 | Stryker Corporation | COMPOSITIONS AND METHODS FOR MINIMALLY-INVASIVE SYSTEMIC DELIVERY OF PROTEINS INCLUDING TGF-β SUPERFAMILY MEMBERS |
SG173632A1 (en) | 2009-02-12 | 2011-09-29 | Stryker Corp | Peripheral administration of proteins including tgf-beta superfamily members for systemic treatment of disorders and disease |
WO2010110974A1 (en) | 2009-03-24 | 2010-09-30 | Stryker Corporation | Methods and compositions for tissue engineering |
US8609127B2 (en) | 2009-04-03 | 2013-12-17 | Warsaw Orthopedic, Inc. | Medical implant with bioactive material and method of making the medical implant |
US20110002897A1 (en) | 2009-06-11 | 2011-01-06 | Burnham Institute For Medical Research | Directed differentiation of stem cells |
WO2011031856A1 (en) | 2009-09-09 | 2011-03-17 | Stryker Corporation | Bmp -7 for use in treating pain induced by injuries and diseases of an articular joint |
US20110224410A1 (en) | 2009-09-17 | 2011-09-15 | Hile David | Buffers for Controlling the pH of Bone Morphogenetic Proteins |
CA2785038A1 (en) | 2009-12-22 | 2011-07-21 | Stryker Corporation | Bmp-7 variants with reduced immunogenicity |
WO2011103598A1 (en) | 2010-02-22 | 2011-08-25 | Biomimetic Therapeutics, Inc. | Platelet-derived growth factor compositions and methods for the treatment of tendinopathies |
JO3340B1 (ar) | 2010-05-26 | 2019-03-13 | Regeneron Pharma | مضادات حيوية لـعامل تمايز النمو 8 البشري |
TW201210612A (en) | 2010-06-03 | 2012-03-16 | Glaxo Group Ltd | Humanised antigen binding proteins |
MX2013001845A (es) | 2010-08-16 | 2013-08-27 | Amgen Inc | Polipetidos que enlazan miostatina, composiciones y metodos. |
US9688735B2 (en) | 2010-08-20 | 2017-06-27 | Wyeth Llc | Designer osteogenic proteins |
CN103079585B (zh) | 2010-08-20 | 2015-09-30 | 惠氏有限责任公司 | 经设计的成骨蛋白 |
TWI761912B (zh) | 2010-11-30 | 2022-04-21 | 日商中外製藥股份有限公司 | 具有鈣依存性的抗原結合能力之抗體 |
US20130085139A1 (en) | 2011-10-04 | 2013-04-04 | Royal Holloway And Bedford New College | Oligomers |
HUE038570T2 (hu) | 2011-11-14 | 2018-10-29 | Regeneron Pharma | Készítmények és eljárások izomtömeg és izomerõ növelésére GDF8 és/vagy aktivin A specifikus antagonizálásával |
SG11201403367YA (en) | 2011-12-19 | 2014-07-30 | Amgen Inc | Variant activin receptor polypeptides, alone or in combination with chemotherapy, and uses thereof |
MY177331A (en) | 2012-06-15 | 2020-09-12 | Pfizer | Improved antagonist antibodies against gdf-8 and uses therefor |
US10034945B2 (en) | 2012-07-13 | 2018-07-31 | Trustees Of Tufts College | Silk powder compaction for production of constructs with high mechanical strength and stiffness |
WO2014039189A1 (en) | 2012-08-01 | 2014-03-13 | Mcnally Elizabeth | Mitigating tissue damage and fibrosis via latent transforming growth factor beta binding protein (ltbp4) |
WO2014030750A1 (ja) | 2012-08-24 | 2014-02-27 | 中外製薬株式会社 | マウスFcγRII特異的Fc抗体 |
CN113831406A (zh) | 2012-08-24 | 2021-12-24 | 中外制药株式会社 | FcγRIIb特异性Fc区变体 |
NZ628446A (en) | 2012-09-13 | 2017-06-30 | Bristol Myers Squibb Co | Fibronectin based scaffold domain proteins that bind to myostatin |
SG11201505960VA (en) | 2013-02-01 | 2015-08-28 | Santa Maria Biotherapeutics Inc | Administration of an anti-activin-a compound to a subject |
CA2908350C (en) | 2013-04-02 | 2023-08-08 | Futa Mimoto | Fc region variant |
CA2911514A1 (en) | 2013-05-06 | 2014-11-13 | Scholar Rock, Inc. | Compositions and methods for growth factor modulation |
TWI655207B (zh) | 2013-07-30 | 2019-04-01 | 再生元醫藥公司 | 抗活化素a之抗體及其用途 |
US10307480B2 (en) | 2014-11-06 | 2019-06-04 | Scholar Rock, Inc. | Anti-pro/latent-myostatin antibodies and uses thereof |
WO2016073906A2 (en) * | 2014-11-06 | 2016-05-12 | Scholar Rock, Inc. | Transforming growth factor-related immunoassays |
PE20171111A1 (es) | 2014-12-19 | 2017-08-07 | Chugai Pharmaceutical Co Ltd | Anticuerpos antimiostatina, polipeptidos que contienen regiones fc variantes, y metodos de uso |
EA201791754A1 (ru) | 2015-02-05 | 2019-01-31 | Чугаи Сейяку Кабусики Кайся | АНТИТЕЛА, СОДЕРЖАЩИЕ ЗАВИСЯЩИЙ ОТ КОНЦЕНТРАЦИИ ИОНОВ АНТИГЕНСВЯЗЫВАЮЩИЙ ДОМЕН, ВАРИАНТЫ Fc-ОБЛАСТИ, IL-8-СВЯЗЫВАЮЩИЕ АНТИТЕЛА И ИХ ПРИМЕНЕНИЯ |
MA41795A (fr) | 2015-03-18 | 2018-01-23 | Sarepta Therapeutics Inc | Exclusion d'un exon induite par des composés antisens dans la myostatine |
CA2982810A1 (en) | 2015-04-15 | 2016-10-20 | Regeneron Pharmaceuticals, Inc. | Methods of increasing strength and functionality with gdf8 inhibitors |
CN113896789A (zh) | 2015-09-15 | 2022-01-07 | 供石公司 | 抗-原肌生长抑制素/潜伏肌生长抑制素抗体及其用途 |
WO2017062835A2 (en) | 2015-10-09 | 2017-04-13 | Sarepta Therapeutics, Inc. | Compositions and methods for treating duchenne muscular dystrophy and related disorders |
CN115073625B (zh) | 2015-10-26 | 2024-01-16 | 哈佛学院院长等 | 还原和氧化的多糖及其使用方法 |
US11359009B2 (en) | 2015-12-25 | 2022-06-14 | Chugai Seiyaku Kabushiki Kaisha | Anti-myostatin antibodies and methods of use |
JP2019504064A (ja) | 2016-01-08 | 2019-02-14 | スカラー ロック インコーポレイテッドScholar Rock,Inc. | 抗プロ/潜在型ミオスタチン抗体およびその使用方法 |
JP6823167B2 (ja) | 2016-06-13 | 2021-01-27 | スカラー ロック インコーポレイテッドScholar Rock,Inc. | ミオスタチン阻害剤の使用および併用療法 |
TW202228778A (zh) | 2016-06-17 | 2022-08-01 | 日商中外製藥股份有限公司 | 抗肌抑素抗體及使用方法 |
WO2018025982A1 (ja) | 2016-08-05 | 2018-02-08 | 中外製薬株式会社 | Il-8関連疾患の治療用又は予防用組成物 |
HUE061656T2 (hu) | 2017-01-06 | 2023-07-28 | Scholar Rock Inc | Metabolikus betegségek kezelése a miosztatin aktiválás gátlásával |
AU2019226551A1 (en) | 2018-03-01 | 2020-10-15 | Regeneron Pharmaceuticals, Inc. | Methods for altering body composition |
CN113195532A (zh) | 2018-12-18 | 2021-07-30 | 瑞泽恩制药公司 | 使用针对瘦素受体、gdf8和活化素a的拮抗剂增加体重和瘦肌肉质量的组合物和方法 |
AU2019406214A1 (en) | 2018-12-21 | 2021-08-05 | Northwestern University | Use of annexins in preventing and treating muscle membrane injury |
WO2020139977A1 (en) | 2018-12-26 | 2020-07-02 | Northwestern University | Use of glucocorticoid steroids in preventing and treating conditions of muscle wasting, aging and metabolic disorder |
JP7375525B2 (ja) * | 2019-12-23 | 2023-11-08 | 株式会社島津製作所 | 患者認証システムおよび患者認証方法 |
JP7397822B2 (ja) | 2021-05-14 | 2023-12-13 | 花王株式会社 | 口腔用貼付シート |
WO2024064842A1 (en) | 2022-09-21 | 2024-03-28 | Regeneron Pharmaceuticals, Inc. | Methods of treating obesity, diabetes, and liver dysfunction |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4766073A (en) * | 1985-02-25 | 1988-08-23 | Zymogenetics Inc. | Expression of biologically active PDGF analogs in eucaryotic cells |
US5350836A (en) * | 1989-10-12 | 1994-09-27 | Ohio University | Growth hormone antagonists |
AU639047B2 (en) | 1989-11-22 | 1993-07-15 | Genentech Inc. | Latency associated peptide and uses therefor |
AU7312891A (en) * | 1990-02-12 | 1991-09-03 | Board Of Regents, The University Of Texas System | Satellite cell proliferation in adult skeletal muscle |
JP3415643B2 (ja) * | 1992-12-04 | 2003-06-09 | 株式会社ミノファーゲン製薬 | 筋ジストロフィー症治療薬 |
EP1333035A3 (en) * | 1993-03-19 | 2004-07-07 | The Johns Hopkins University School Of Medicine | Growth differentiation factor-8 |
US5994618A (en) * | 1997-02-05 | 1999-11-30 | Johns Hopkins University School Of Medicine | Growth differentiation factor-8 transgenic mice |
ATE305036T1 (de) | 1994-07-08 | 2005-10-15 | Univ Johns Hopkins Med | Wachstums-differenzierungsfaktor-11 |
US5616561A (en) | 1995-03-31 | 1997-04-01 | Regents Of The University Of California | TGF-β antagonists as mitigators of radiation-induced tissue damage |
AU6274298A (en) | 1997-02-05 | 1998-08-25 | Johns Hopkins University School Of Medicine, The | Growth differentiation factor-8 |
DK2045322T3 (en) | 1997-07-14 | 2015-10-05 | Université de Liège | DOUBLE MUSCULAR FOR MAMMALS |
US6656475B1 (en) * | 1997-08-01 | 2003-12-02 | The Johns Hopkins University School Of Medicine | Growth differentiation factor receptors, agonists and antagonists thereof, and methods of using same |
WO1999040181A1 (en) | 1998-02-05 | 1999-08-12 | The Johns Hopkins University School Of Medicine | Growth differentiation factor-8 |
US6369201B1 (en) | 1998-02-19 | 2002-04-09 | Metamorphix International, Inc. | Myostatin multimers |
-
1994
- 1994-03-18 EP EP03006413A patent/EP1333035A3/en not_active Ceased
- 1994-03-18 JP JP6521293A patent/JPH09507829A/ja active Pending
- 1994-03-18 WO PCT/US1994/003019 patent/WO1994021681A1/en active IP Right Grant
- 1994-03-18 EP EP94912274A patent/EP0690873B1/en not_active Expired - Lifetime
- 1994-03-18 DK DK94912274T patent/DK0690873T3/da active
- 1994-03-18 DE DE69432815T patent/DE69432815T2/de not_active Expired - Lifetime
- 1994-03-18 ES ES94912274T patent/ES2201076T3/es not_active Expired - Lifetime
- 1994-03-18 US US08/525,596 patent/US5827733A/en not_active Expired - Lifetime
- 1994-03-18 CA CA002157577A patent/CA2157577C/en not_active Expired - Lifetime
-
1998
- 1998-10-23 US US09/177,860 patent/US6096506A/en not_active Expired - Lifetime
-
2000
- 2000-08-01 US US09/629,938 patent/US6500664B1/en not_active Expired - Lifetime
-
2002
- 2002-12-31 US US10/335,483 patent/US7179884B2/en not_active Expired - Fee Related
-
2004
- 2004-01-06 JP JP2004001012A patent/JP2004121265A/ja active Pending
-
2005
- 2005-11-10 JP JP2005326630A patent/JP2006117682A/ja active Pending
-
2007
- 2007-01-29 US US11/700,267 patent/US7534432B2/en not_active Expired - Fee Related
- 2007-05-09 JP JP2007125060A patent/JP2007306920A/ja active Pending
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2004504826A (ja) * | 2000-07-27 | 2004-02-19 | ザ ジョーンズ ホプキンス ユニバーシティー スクール オブ メディシン | プロミオスタチンペプチドおよびその使用法 |
JP2007535912A (ja) * | 2003-12-31 | 2007-12-13 | シェーリング−プラウ・リミテッド | 中和エピトープベースの増殖増強性ワクチン |
Also Published As
Publication number | Publication date |
---|---|
ES2201076T3 (es) | 2004-03-16 |
WO1994021681A1 (en) | 1994-09-29 |
DE69432815D1 (de) | 2003-07-17 |
EP0690873B1 (en) | 2003-06-11 |
JP2004121265A (ja) | 2004-04-22 |
US7534432B2 (en) | 2009-05-19 |
EP0690873A1 (en) | 1996-01-10 |
US6500664B1 (en) | 2002-12-31 |
CA2157577A1 (en) | 1994-09-29 |
EP1333035A3 (en) | 2004-07-07 |
EP0690873A4 (en) | 2000-11-22 |
US20070185321A1 (en) | 2007-08-09 |
JP2006117682A (ja) | 2006-05-11 |
CA2157577C (en) | 2009-11-17 |
JP2007306920A (ja) | 2007-11-29 |
US7179884B2 (en) | 2007-02-20 |
EP1333035A2 (en) | 2003-08-06 |
US6096506A (en) | 2000-08-01 |
DK0690873T3 (da) | 2003-09-29 |
US5827733A (en) | 1998-10-27 |
DE69432815T2 (de) | 2003-12-11 |
US20030120058A1 (en) | 2003-06-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JPH09507829A (ja) | 増殖分化因子−8 | |
CA2194660C (en) | Growth differentiation factor-11 | |
US6204047B1 (en) | Growth differentiation factor-10 | |
US7074574B2 (en) | Method of detecting growth differentiation factor-7 (GDF-7) using GDF-7 antibodies | |
JP3645258B2 (ja) | 増殖分化因子−5 | |
JPH09503903A (ja) | 増殖分化因子−6 | |
JPH08505771A (ja) | 増殖分化因子−3 | |
JP2004091466A (ja) | 増殖分化因子−9 | |
EP0770089B1 (en) | Growth differentiation factor-12 | |
JPH11508125A (ja) | 繊維芽細胞増殖因子相同因子−1(fhf−1)および使用方法 | |
US20030211541A1 (en) | Growth differentiation factor-14 | |
US20060140941A1 (en) | Growth differentiation factor-3 | |
US6713302B1 (en) | Growth differentiation factor-6 | |
US20020161204A1 (en) | Methods of detecting a liver disorder |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20031208 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20040304 |
|
A912 | Re-examination (zenchi) completed and case transferred to appeal board |
Free format text: JAPANESE INTERMEDIATE CODE: A912 Effective date: 20040401 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20061012 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20061023 |